Europe Jan 19, 2023 Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug Jan 17, 2023 PamGene, Alithea Genomics, Lausanne University get €1M for Pan-Cancer Blood Test Jan 10, 2023 Sophia Genetics to Commercialize MSK-ACCESS Clinical Liquid Biopsy Test Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Jan 6, 2023 In Brief This Week: Datar Cancer Genetics, Daiichi Sankyo, ProPhase Labs, Innovent Biologics Jan 5, 2023 AstraZeneca to Evaluate C2i Genomics' Cancer Detection, Monitoring Platform Jan 5, 2023 Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer Jan 4, 2023 Orano Med Commences Phase I Trial of Lead Radiopharmaceutical in GRPR-Expressing Solid Tumors Jan 4, 2023 Nuvectis Partners With ENGOT, GOG Foundation on Phase Ib Ovarian Cancer Trial of HSF1 Inhibitor Jan 3, 2023 Evaxion Cleared by FDA to Begin Phase IIb Trial of Cancer Vaccine, Keytruda in Melanoma Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 21, 2022 Jazz Takes Up Option on Zymeworks' HER2-Targeted Bispecific Antibody Dec 20, 2022 Multiomic Study Points to New Colorectal Cancer Risk Contributors Dec 20, 2022 NICE Backs Enhertu via Managed Access Program for Certain HER2-Positive Breast Cancer Patients Dec 19, 2022 AstraZeneca's Imfinzi Fails to Meet Primary Endpoint in PD-L1-high NSCLC Dec 19, 2022 SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit Dec 16, 2022 Everything Genetic, Berkshire and Surrey Pathology Services Jointly Launch Cancer NGS Service in UK Dec 14, 2022 Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors Dec 13, 2022 Novartis' Pluvicto Approved in Europe for PSMA-Positive Castration-Resistant Prostate Cancer Dec 13, 2022 Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer